Difference between revisions of "Melanoma, KIT-mutated"
Jump to navigation
Jump to search
m (→Chemotherapy) Tag: visualeditor |
Tag: visualeditor |
||
| Line 30: | Line 30: | ||
'''Biomarker eligibility criteria''' | '''Biomarker eligibility criteria''' | ||
| − | * Gene: KIT | + | *Gene: KIT |
| − | * Alteration: amplification and mutation | + | *Alteration: amplification and mutation |
| − | * Acceptable methods of measurement: PCR or HPLC | + | *Acceptable methods of measurement: PCR or HPLC |
====Chemotherapy==== | ====Chemotherapy==== | ||
| Line 54: | Line 54: | ||
====Chemotherapy==== | ====Chemotherapy==== | ||
| − | *[[Imatinib (Gleevec)]] 400 mg PO twice per day | + | *[[Imatinib (Gleevec)]] 400 mg PO once or twice per day |
'''Continued indefinitely''' | '''Continued indefinitely''' | ||
Revision as of 23:30, 8 January 2020
| Section editor | |
|---|---|
 |
Elizabeth Buchbinder, MD Dana-Farber Cancer Institute Boston, MA |
Note: these are regimens tested in biomarker-specific populations, please see the main melanoma page for other regimens.
1 regimens on this page
2 variants on this page
|
Advanced or metastatic disease, TKI-naive
Imatinib monotherapy
| back to top |
Variant #1, pre-planned escalation
| Study | Evidence |
|---|---|
| Hodi et al. 2013 (BUS255) | Phase II |
Biomarker eligibility criteria
- Gene: KIT
- Alteration: amplification and mutation
- Acceptable methods of measurement: PCR or HPLC
Chemotherapy
- Imatinib (Gleevec) as follows:
- Starting dose: 400 mg PO once per day
- Upon progression: 400 mg PO twice per day
Continued indefinitely
Variant #2
| Study | Evidence |
|---|---|
| Carvajal et al. 2011 | Phase II |
Patients had melanomas arising from mucosal, acral, and chronically sun-damaged skin with KIT mutations or amplifications.
Chemotherapy
- Imatinib (Gleevec) 400 mg PO once or twice per day
Continued indefinitely
References
- Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J, Pavlick AC, Fusco A, Cane L, Takebe N, Vemula S, Bouvier N, Bastian BC, Schwartz GK. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011 Jun 8;305(22):2327-34. contains protocol link to PMC article PubMed
- BUS255: Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, Collichio FA, Ernstoff MS, Heinrich MC, Beadling C, Zukotynski KA, Yap JT, Van den Abbeele AD, Demetri GD, Fisher DE. Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin. J Clin Oncol. 2013 Sep 10;31(26):3182-90. Epub 2013 Jun 17. link to original article contains verified protocol link to PMC article PubMed